Literature DB >> 12417456

Motivation, reward, and Parkinson's disease: influence of dopatherapy.

V Czernecki1, B Pillon, J L Houeto, J B Pochon, R Levy, B Dubois.   

Abstract

"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417456     DOI: 10.1016/s0028-3932(02)00108-2

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  87 in total

1.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

Review 2.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

3.  Apathy and depression: separate factors in Parkinson's disease.

Authors:  Lindsey Kirsch-Darrow; Michael Marsiske; Michael S Okun; Russell Bauer; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2011-11       Impact factor: 2.892

4.  Executive function in Parkinson's disease: contributions of the dorsal frontostriatal pathways to action and motivation.

Authors:  Susan M Ravizza; John Goudreau; Mauricio R Delgado; Sandra Ruiz
Journal:  Cogn Affect Behav Neurosci       Date:  2012-03       Impact factor: 3.282

5.  Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?

Authors:  V Czernecki; B Pillon; J L Houeto; M L Welter; V Mesnage; Y Agid; B Dubois
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

7.  The late positive potential, emotion and apathy in Parkinson's disease.

Authors:  J Dietz; M M Bradley; J Jones; M S Okun; W M Perlstein; D Bowers
Journal:  Neuropsychologia       Date:  2013-01-12       Impact factor: 3.139

8.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

9.  Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task.

Authors:  Robb B Rutledge; Stephanie C Lazzaro; Brian Lau; Catherine E Myers; Mark A Gluck; Paul W Glimcher
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

Review 10.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.